在CYP3A5*6与*3功能丧失等位基因携带者中较低剂量-正常化的塔克罗利斯暴露:在脏移植接受者中进行的一项长度回顾性现实世界研究
Amar D Levens1, Dirk Jan A R Moes1, Yanick Boer1
1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Clinical pharmacology and therapeutics
|December 23, 2025
概括
基因变异CYP3A5*6显著降低了移植患者,特别是非洲血统患者的塔克罗利暴露. 这一发现解决了药物基因组学中的不足,并促进了健康公平.
科学领域:
- 药物基因组学 药物基因组学
- 移植医学 移植医学
- 临床药理学 临床药理学
背景情况:
- 药物基因组研究历史上低于非欧洲人口的代表性.
- 该CYP3A5*6变体在非洲血统中很常见,但在欧洲人中很少见.
- 塔克罗利斯的剂量受到CYP3A5.5的遗传变异的影响.
研究的目的:
- 为了研究CYP3A5*6携带对移植接受者的塔克罗利暴露的影响.
- 解决药物基因组学研究中遗传变异的不足.
- 探索药物反应中的种族差异.
主要方法:
- 在67个国家对1461名移植接受者进行了回顾性纵向队列研究.
- 分析了4,293个剂量正常化的塔克罗利斯24小时曲线下面积 (AUC0-24) 测量结果.
- 根据临床因素和祖先调整的线性混合效应模型 (基于HLA的PC,出生国).
主要成果:
- 与CYP3A5*3载体 (P=0.015) 相比,CYP3A5*6载体表现出17%较低的剂量正常化的塔克罗利斯AUC0-24 (P=0.015).
- 灵敏度分析证实,在移植后的第一年内,暴露率较低 (20%较低C0;P=0.011),持续持续.
- 非洲起源独立地与23%更高的塔克罗利斯AUC0-24 (P<0.001) 相关.
结论:
- 这项研究是第一个在CYP3A5*6和CYP3A5*3功能丧失等位基因之间显示出差异性塔克罗利斯暴露效应的研究.
- 这些发现突显了CYP3A5*6的临床意义及其对塔克罗利斯药理动学的影响.
- 结果有助于弥合药物基因组学中的种族差距,并促进健康公平.
相关概念视频
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
186
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
186
Renal Failure: Dose Adjustments
401
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
401
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
197
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
197
Pharmacokinetics in Pediatric Patients: Drug Excretion
191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
Kidney Transplant I: Introduction
304
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
304


